PT - JOURNAL ARTICLE AU - Adams, Gordon AU - Moreno, Gage K. AU - Petros, Brittany A. AU - Uddin, Rockib AU - Levine, Zoe AU - Kotzen, Ben AU - Messer, Katelyn AU - Dobbins, Sabrina T. AU - DeRuff, Katherine C. AU - Loreth, Christine AU - Brock-Fisher, Taylor AU - Schaffner, Stephen F. AU - Chaluvadi, Sushma AU - Kanjilal, Sanjat AU - Luban, Jeremy AU - Ozonoff, Al AU - Park, Daniel AU - Turbett, Sarah AU - Siddle, Katherine J. AU - MacInnis, Bronwyn L. AU - Sabeti, Pardis AU - Lemieux, Jacob TI - The 2022 RSV surge was driven by multiple viral lineages AID - 10.1101/2023.01.04.23284195 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.04.23284195 4099 - http://medrxiv.org/content/early/2023/01/05/2023.01.04.23284195.short 4100 - http://medrxiv.org/content/early/2023/01/05/2023.01.04.23284195.full AB - The US experienced an early and severe respiratory syncytial virus (RSV) surge in autumn 2022. Despite the pressure this has put on hospitals and care centers, the factors promoting the surge in cases are unknown. To investigate whether viral characteristics contributed to the extent or severity of the surge, we sequenced 105 RSV-positive specimens from symptomatic patients diagnosed with RSV who presented to the Massachusetts General Hospital (MGH) and its outpatient practices in the Greater Boston Area. Genomic analysis of the resulting 77 genomes (54 with >80% coverage, and 23 with >5% coverage) demonstrated that the surge was driven by multiple lineages of RSV-A (91%; 70/77) and RSV-B (9%; 7/77). Phylogenetic analysis of all US RSV-A revealed 12 clades, 4 of which contained Massachusetts and Washington genomes. These clades individually had times to most recent common ancestor (tMRCA) between 2014 and 2017, and together had a tMRCA of 2009, suggesting that they emerged well before the COVID-19 pandemic. Similarly, the RSV-B genomes had a tMRCA between 2016 and 2019. We found that the RSV-A and RSV-B genomes in our sample did not differ statistically from the estimated clock rate of the larger phylogenetic tree (10.6 and 12.4 substitutions per year, respectively). In summary, the polyphyletic nature of viral genomes sequenced in the US during the autumn 2022 surge is inconsistent with the emergence of a single, highly transmissible causal RSV lineage.Competing Interest StatementDr. Sabeti is a co-founder and consultant at Sherlock Biosciences Inc. and Delve Bio, and is a Board Member of Danaher Corporation; she holds equity in all three companies. She has several patents related to diagnostics, genome sequencing, and informatics, including two patents licensed to Sherlock Biosciences.Funding StatementThis work was sponsored in part by the Centers for Disease Control Broad Agency Announcement (75D30120C09605 to B.L.M.), the Howard Hughes Medical Institute Investigator award to P.C.S., the National Institute of Allergy and Infectious Diseases (U19AI110818 to P.C.S), the Massachusetts Consortium on Pathogen Readiness (to J.E.L and to J.L.), and the National Institute of General Medical Sciences (T32GM007753 and T32GM144273 to B.A.P. and Z.C.L.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Massachusetts General Hospital gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw reads and assembled genomes are submitted to Genbank under PRJNA904288. Files associated with the Bayesian analyses are available on GitHub at https://github.com/bpetros95/rsv-2022.